Nov. 2, 2011
/PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures, and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical applications, announced its recent exhibition of the BoneScalpel™ Ultrasonic Bone Cutting System and the SonaStar® Ultrasonic Surgical Aspiration System at the European Association of Neurosurgical Societies ("EANS"), which was held in
October 9-14, 2011
. The meeting provided Company representatives the opportunity to demonstrate both systems to a significant percentage of the approximately 1,900 delegates present.
EANS' stated goals are to promote enhanced scientific knowledge and the exchange of information between those in different cultures and training systems throughout
The SonaStar is used by Neurosurgeons and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt™ bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.
Neurosurgeons, Orthopedic Surgeons and Maxillo-facial/Reconstructive Surgeons use BoneScalpel as a tissue specific osteotomy device to make precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. The device offers the convenience and speed of a power instrument while minimizing the peril associated with rotary sharps.
"We were excited to be part of this meeting of European experts in neurosurgery and spine surgery," said
Michael A. McManus, Jr.
, President and Chief Executive Officer of Misonix. "It exemplifies our commitment to providing products that can contribute to better patient outcomes and to supporting organizations that promote best practices in medicine."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of
annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at
With the exception of historical information contained in this press release, content herein may contain "forward-looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.